1 results match your criteria: "Montreal Neurological Institute (S.V.[Affiliation]"
Neurology
March 2020
From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.
Objective: To investigate relationships between flortaucipir (FTP) uptake, age, and established Alzheimer disease (AD) markers in asymptomatic adults at increased risk of AD.
Methods: One-hundred nineteen individuals with a family history of AD (Presymptomatic Evaluation of Experimental or Novel Treatments of Alzheimer's Disease [PREVENT-AD] cohort, mean age 67 ± 5 years) underwent tau-PET ([F]FTP), β-amyloid (Aβ)-PET ([F]NAV4694 [NAV]), and cognitive assessment. Seventy-four participants also had CSF phosphorylated tau and total tau data available.